ClinicalTrials.Veeva

Menu

iTBS on Negative Symptoms and Cognitive Function in Schizophrenia

C

Central South University

Status

Completed

Conditions

Schizophrenia

Treatments

Device: Sham stimulation
Device: Intermittent theta burst stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT05137158
WU202110TBS

Details and patient eligibility

About

The negative symptoms and cognitive deficits are common in patients with schizophrenia, and do not respond well to antipsychotics. The effective treatments for negative symptoms and cognitive impairment are still to be explored. rTMS is a safe and non-invasive physical treatment, some studies has been indicated that the high frequency rTMS could increase the excitability of cortex, and has potentials to improve negative symptoms and cognitive function in schizophrenia. In this study, we explore the effects of iTBS on negative symptoms and cognitive function based on identifying the brain network connection of schizophrenia symptoms.

Full description

The negative symptoms and cognitive deficits are two core symptoms in patients with schizophrenia, and do not respond well to antipsychotics. There are many researches on the biological mechanism of these two symptoms, and some studies indicated that these two symptoms maybe related to the dysfunction of prefrontal cortex and deficiency of dopamine. rTMS is a safe and non-invasive physical treatment, some studies has been indicated that the high frequency rTMS could increase the excitability of cortex, and has potentials to improve negative symptoms and cognitive function in schizophrenia.Therefore, this study explore the efficacy of iTBS on negative symptoms and cognitive deficits in schizophrenia based on identifying the brain network connection of schizophrenia symptoms.

Firstly, we have used neuroimaging to find the left prefrontal cortex that is responsible for negative symptoms and cognitive function in schizophrenia. Then,we design this randomized double-blind sham-controlled clinical trial. Patients with schizophrenia will be randomly treated with iTBS or sham condition to the left dorsolateral prefrontal cortex(L-DLPFC) for continuous 10 days, theL-DLPFC will be targeted utilizing the localite neuronavigation system. The follow-ups are set at baseline, the 11th day and the 30th day after the end of treatment. The main outcome measures include the change in MCCB score, PANSS score, SANS score, SAPS score and the resting-state functional magnetic resonance imaging data.

Enrollment

66 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with schizophrenia in accordance with DSM-5
  2. The disease duration ≤8 years
  3. Received a steady dose of antipsychotic medication for least 4 weeks
  4. The Global Deficit Score of MCCB ≥0.5 or the PANSS negative subscore ≥20
  5. No obvious extrapyramidal side effects caused by antipsychotic drugs
  6. Informed Consent

Exclusion criteria

  1. Diagnosed with other mental disease in accordance with DSM-5
  2. Combined with other severe physiological disease
  3. Used antidepressants, mood stabilizer, or other psychoactive substances before
  4. Drug or alcohol abuse
  5. Pregnant or lactating
  6. Contraindication to rTMS
  7. Received rTMS or electroconvulsive therapy in the past 1 month

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

66 participants in 2 patient groups

iTBS stimulation
Experimental group
Description:
The patients in iTBS stimulation group will receive iTBS stimulation on the target of the left dorsolateral prefrontal cortex for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
Treatment:
Device: Intermittent theta burst stimulation
Sham stimulation
Sham Comparator group
Description:
The participants in sham stimulation will receive sham stimulation, as the coil vertical to the brain surface, for 10 consecutive days and 3 times per day.There will have at least 30 minutes interval between each intervention.
Treatment:
Device: Sham stimulation

Trial contacts and locations

1

Loading...

Central trial contact

Renrong Wu, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems